Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sunniva Inc SNNVF

Healthcare Biotechnology Cannabis
Sunniva Inc. is a Canada-based company. The Company is not engaged in any business.


GREY:SNNVF - Post by User

Sunniva Inc > Listing Restrictions- Investor exposure
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by URLaughable3on Apr 24, 2018 3:17pm
92 Views
Post# 27933866

RE:RE:RE:RE:RE:Listing Restrictions- Investor exposure

RE:RE:RE:RE:RE:Listing Restrictions- Investor exposureHey 4Life, maybe fully read a post before dropping your wisdom with that dose of attitude eh. We all know about the BC facility and it’s focus, we are also well aware of the Cali market size. The statement was clearly angled at supplying NHS prior to B.C. production commencing. So from July to December 2018. This would mean they could sell their own bud to patients instead of writing scripts for them to buy elsewhere (higher margins on 90k+ patients). 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities